Check-Cap Announces Receipt Of Nasdaq Minimum Bid Price Notification
Check-Cap Announces Receipt Of Nasdaq Minimum Bid Price Notification
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
Further, the Rules also provide the Company a compliance period of 180 calendar days to regain compliance. According to the Letter, the Company has from December 23, 2021, or until June 21, 2022, to regain compliance with the minimum bid price requirement. The Company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional time if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period.
If the Company cannot demonstrate compliance by the end of the 180-day period, the Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.
The Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, Check-Cap's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "CHEK".
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
纳斯达克(以下简称：CHEKZ)是一家推进C-SCAN®开发的临床期医疗诊断公司，C-SCAN®是第一种也是唯一一种在息肉可能转化为结直肠癌之前检测出息肉的方便患者、免准备的筛查测试。Check-Cap Ltd.(以下简称“Check-Cap”)今天宣布，公司收到了纳斯达克上市资格委员会的一封函件(以下简称“函件”)，表明公司没有遵守上市规则中规定的继续上市的最低出价要求。这要求上市证券维持每股1.00美元的最低买入价。
Further, the Rules also provide the Company a compliance period of 180 calendar days to regain compliance. According to the Letter, the Company has from December 23, 2021, or until June 21, 2022, to regain compliance with the minimum bid price requirement. The Company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional time if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period.
此外，规则还为公司提供了180个历日的合规期，以重新获得合规。根据这封信，该公司必须在2021年12月23日或2022年6月21日之前重新遵守最低投标价格要求。如果在这180天期间的任何时间，其普通股的收盘价在至少连续十个工作日内至少为1美元，本公司可以重新获得合规，在这种情况下，本公司将获得合规的书面确认，这一事项将被了结。如果本公司在最初的180天期限后仍未恢复合规，如果本公司符合公开持股市值继续上市的要求以及纳斯达克资本市场的所有其他初始上市标准(投标价格要求除外)，则本公司可能有资格获得额外的合规时间，并将需要在第二合规期限内提供书面通知，表明其打算弥补不足之处。
If the Company cannot demonstrate compliance by the end of the 180-day period, the Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.
如果公司在180天期限结束前仍不能证明其遵守规定，纳斯达克的工作人员将通知公司其普通股将被摘牌。
The Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, Check-Cap's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "CHEK".
该函件对本公司的纳斯达克上市或其普通股的交易并无即时影响，而在宽限期内(可予延长)，Check-Cap的普通股将继续以“CHEK”的编号在纳斯达克资本市场买卖。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧